Quantification of CPT13 in rat plasma using LC–MS/MS for a pharmacokinetic study
Qing Yong Li,Lin Su,Yuan Gang Zu,Lin Zhang,Yang Gao,Chun Cheng Wang,Qiao Chu Zhu,Xiao Qiu Deng
DOI: https://doi.org/10.1016/j.jchromb.2011.01.001
IF: 3.318
2011-01-01
Journal of Chromatography B
Abstract:A new, simple, sensitive and specific reversed-phase high performance liquid chromatographic (HPLC) method using tandem mass spectrometry detection was initially developed and validated for the analysis of 10-(2-pyrazolyl-ethoxy)-(20S)-camptothecin (CPT13) in rat plasma. Pretreatment of the sample obtained from plasma involved a single protein precipitation step with using acetonitrile containing 0.1% formic acid. An aliquot of 20μl was injected into a C-18 column. The chromatographic separation was achieved using the mobile phase consisting of acetonitrile:water (35:65) at a flow rate of 1.0mL/min. The total run time for each sample was 10min, and camptothecin (CPT, IS) and CPT13 were well separated with retention times of 5.1min and 5.6min, respectively. Detection was performed using a triple quadrupole tandem mass spectrometer in multiple reaction monitoring (MRM) mode via an electrospray ionization (ESI) source. The calibration curve was linear (r2=0.9998) over the concentration range of 1–1000ng/mL, with a LLOQ of 1ng/mL for CPT13. The inter- and intra-day precision (%R.S.D.) were <2.58% and 6.28%, respectively, and the accuracies (%) were within the range of 97.34–110.67%. CPT13 in rat plasma was stable when stored at −20°C or 4°C for three freeze–thaw cycles, The method was employed for the first time during pharmacokinetic studies of CPT13 in rats following a single intravenous dose (0.1mg/kg) and three different oral doses (50mg/kg, 30mg/kg, and 10mg/kg). This fully validated method was successfully applied to a pharmacokinetic study of CPT13 in rats.